Nina Shah, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Articles

Investigational Agents for Relapsed/Refractory Myeloma

August 24th 2021

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, review additional emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.

CARTITUDE-1 and CARTITUDE-2 Trials in Multiple Myeloma

August 24th 2021

Multiple myeloma experts evaluate the safety and efficacy of ciltacabtagene autoleucel for RRMM, as seen in updated data presented at ASCO 2021 for the CARTITUDE-1 and CARTITUDE-2 studies.

Using CAR T Therapy for Relapsed/Refractory Myeloma

August 17th 2021

Nina Shah, MD, leads the discussion on the role of CAR T-cell therapy, including idecabtagene vicleucel, for the management of RRMM.

Role of BCMA-Targeted Agents in Myeloma

August 17th 2021

Experts in multiple myeloma review the use of belantamab mafodotin as described in the DREAMM-2 trial and discuss the management of the associated ototoxicity.

Treatment of Relapsed/Refractory Myeloma: Novel Agents

August 10th 2021

Cristina Gasparetto, MD; Sagar Lonial, MD, FACP; Joseph Mikhael, MD; and Nina Shah, MD, discuss emerging agents available for the treatment of RRMM.

PI-Based Combinations for Relapsed Myeloma

August 10th 2021

A review of data from key clinical trials, including CANDOR and IKEMA, for relapsed/refractory multiple myeloma.

CASSIOPEIA Trial of Dara-VTd in Transplant-Eligible Myeloma

August 3rd 2021

Joseph Mikhael, MD, reviews updated results presented at the 2021 ASCO annual meeting of the phase 3 CASSIOPEIA trial for NDMM, and Nina Shah, MD, comments on how the data may inform the addition of daratumumab to triplet therapy at relapse.

Using IMiD-Based Strategies for Relapsed Myeloma

August 3rd 2021

Multiple myeloma experts discuss the role of pomalidomide-containing regimens for the treatment of RRMM.

Approaching Treatment of Relapsed/Refractory Myeloma

July 27th 2021

Factors to consider when approaching therapy selection for patients with multiple myeloma disease progression.

Role of MRD Assessment in Myeloma

July 27th 2021

Cristina Gasparetto, MD, leads the discussion on whether MRD testing can influence treatment decisions for newly diagnosed multiple myeloma.

Improving Maintenance Therapy for Myeloma

July 20th 2021

Multiple myeloma experts share their thoughts on improving on currently available maintenance therapy, particularly for high-risk patients, and review their personal approaches to maintenance therapy for standard- and high-risk disease.

High-Risk Multiple Myeloma: Selecting Initial Therapy

July 20th 2021

Sagar Lonial, MD, FACP, leads the discussion on selecting the optimal proteasome inhibitor, bortezomib or carfilzomib, for patients with high-risk multiple myeloma.

Standard Induction for Newly Diagnosed Symptomatic Myeloma

July 13th 2021

Experts in multiple myeloma comment on standard induction therapy for patients with newly diagnosed symptomatic myeloma and consider recommended triplet regimens.

Overview of Newly Diagnosed Multiple Myeloma

July 13th 2021

Keith Stewart, MD, ChB, MBA; Sagar Lonial, MD, FACP; Cristina Gasparetto, MD; Joseph Mikhael, MD; and Nina Shah, MD, discuss the diagnostic work-up for a patient with newly diagnosed multiple myeloma and the impact of age and frailty scores on transplant eligibility.

ASH Takeaways and Future Directions for Multiple Myeloma

March 11th 2021

Paul G. Richardson, MD; Nina Shah, MD; David Siegel, MD, PhD; and Saad Z. Usmani, MD, provide closing thoughts and key takeaways on multiple myeloma from the 2020 ASH Virtual Meeting and future directions for disease management. 

Sequencing BCMA-Targeted Agents in RRMM

March 11th 2021

Insights on approaching the sequencing of BCMA-targeted agents and whether antigen loss is considered an issue in RRMM. 

Non-BCMA Specific Targets in RRMM

March 11th 2021

Examining non-BCMA BiTE (bispecific T-cell engager) approaches to therapy, such as talquetamab and BFCR4350A, for the treatment of RRMM. 

Investigational BCMA Targets in RRMM

March 4th 2021

Exploring other investigational BCMA-targeting agents such as teclistamab, AMG 701, and TNB-383B for the management of RRMM. 

Targeting BCMA and CAR T Therapy in RRMM

March 4th 2021

Nina Shah, MD, leads the conversation of using BCMA-targeted antibody-drug conjugate belantamab mafodotin, and the emerging role of CAR T-cell therapy when treating RRMM. 

Emerging Novel Agents in RRMM

February 25th 2021

Paul G. Richardson, MD, reviews early data presented at ASH 2020 on the use of CELMoDs as well as melflufen for the management of RRMM. 